Shorter regimen for multi drug resistant tuberculosis cures more than 80% of patientsBMJ 2016; 355 doi: http://dx.doi.org/10.1136/bmj.i5807 (Published 27 October 2016) Cite this as: BMJ 2016;355:i5807
- Sophie Cousins
A nine month treatment regimen for multiple drug resistant tuberculosis (MDR-TB) patients across nine African countries has shown a success rate of more than 80%, according to results announced at the World Conference on Lung Health in Liverpool, UK.
The results give further impetus for the shortened treatment regimen to be widely adopted, those involved with the study said.
The previous standard regimen for treating MDR-TB lasted for at least 20 months and had a cure rate of less than 55%, often with severe side effects including hearing loss. The treatment consisted …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial